Primary Sclerosing Cholangitis in Childhood is Associated with Abnormalities in Cystic Fibrosis–Mediated Chloride Channel Function
Objective
To determine whether primary sclerosing cholangitis (PSC) in childhood is associated with abnormalities in cystic fibrosis transmembrane conductance regulator (CFTR).
Study design
Subjects with PSC diagnosed in childhood (n = 20) were recruited from Children’s Hospital. Subjects had testing with sweat chloride concentration, nasal transmembrane potential difference, and extensive genetic analysis of the CFTR gene. Disease control subjects consisted of 14 patients with inflammatory bowel disease alone and no liver disease. t Tests were performed to determine statistical significance.
Results
In the PSC group, CFTR chloride channel function (ΔChloride free + isoproterenol) was markedly diminished at −8.6 ± 8.2 mV (reference range: −24.6 ± 10.4 mV). In contrast, disease control subjects had normal function, at −17.8 ± 9.7 mV (P = .008). Sweat chloride concentration in subjects with PSC was greater than in disease control subjects (20.8 ± 3.4 mmol/L vs 12.0 ± 1.6 mmol/L, P = .045). Comprehensive CFTR genotyping revealed that 5 of 19 (26.3%) subjects with PSC had a CFTR mutation or variant, compared with 6 of 14 (42.9%) disease control subjects.
Conclusions
There is a high prevalence of CFTR-mediated ion transport dysfunction in subjects with childhood PSC.
Abbreviations: CF, Cystic fibrosis, CFTR, Cystic fibrosis transmembrane conductance regulator, ERCP, Endoscopic retrograde cholangiopancreatography, IBD, Inflammatory bowel disease, MRCP, Magnetic resonance cholangiopancreatography, NTPD, Nasal transmembrane potential difference, PPAR, Peroxisome proliferator activated receptor, PSC, Primary sclerosing cholangitis
To access this article, please choose from the options below
Supported by the Thrasher Research Fund (grant 02820-4) and The General Clinical Research Centers at Children’s Hospital Boston (NIH M01 RR02172) and The Beth Israel Deaconess Medical Center (NIH M01 RR01032). Dr Pall was supported in part by the Harvard/MIT Clinical Investigator Training Program. This project was also partially funded by Genome Canada through the Ontario Genomics Institute as per research agreement 2004-OGI-3-05. The study sponsors did not have a role in the study design, data analysis, or preparation of the manuscript.
PII: S0022-3476(07)00330-7
doi:10.1016/j.jpeds.2007.03.062
© 2007 Mosby, Inc. All rights reserved.
Refers to article:
- What is the Role of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Primary Sclerosing Cholangitis?
